HER2 dual targeting with trastuzumab in combination with pertuzumab is nowadays the gold standard therapeutic approach for HER2+ breast cancer in the neoadjuvant setting and in the first-line treatment of metastatic disease. The gene discussed is ERBB2; the disease is breast cancer.